Pesticides, Agent Orange, and potential environmental risk factors for the development of Parkinson’s disease (PD) continue to make the news. Patients and families may be comforted by headlines on chemicals and Parkinson’s, most of which they may never be exposed to. The recent report by Goldman and colleagues from the Parkinson’s Institute, a Parkinson'a Foundation Center of Excellence in Sunnyvale, CA, may open some eyes to environmental exposures and Parkinson’s disease risk.
Parkinson's Today Blog
Recently the U.S. Food and Drug Administration (FDA) has been making headlines with multiple press releases and statements which cover several drugs commonly consumed by Parkinson’s disease patients. It is critical that the Parkinson’s disease patient, as well as his or her family, fully understand FDA lingo. Below is information drawn directly from the FDA’s website and from FDA press releases spanning the past decade.
Francis Crick, one of the most famous scientists of our generation, described a double helix structure that is now known to characterize human DNA (this discovery was published in 1953 along with his colleague James Watson). Later, in the 1970s, Crick discussed a wish-list for future discoveries, including the use of light to control human cells.
People with Parkinson’s disease (PD) know the huge difference missed medication dosages can add up to. In some cases, missed medication dosages can lead to complications such as falling and severe mood swings. The results of a study from the United Kingdom conducted by Derry and colleagues should serve as a wake-up call to hospitals around the globe. The study’s authors carefully examined surgical admissions to the Aberdeen Royal Infirmary over an 18 month period.
The recent removal from the United States market of the A class of medications used to treat Parkinson's disease. Agonists enhance the activity of a neurotransmitter – in this case, dopamine.
In this month's issue of the Lancet Neurology, the PD SURG trial results (conducted by a multicenter team of collaborative investigators from all over Britain) are including a one year follow-up of Parkinson's disease A surgical treatment for Parkinson's disease. A special wire (lead) is inserted into a specific area of the brain responsible for movement.
This month a report appeared in the New England Journal of Medicine by Snijders and Bloem about a patient they encountered in their Parkinson's Foundation Center of Excellence. The report was accompanied by a dramatic video revealing a late-stage Parkinson’s disease (PD) patient with severe ambulation difficulties and Temporary, involuntary inability to take a step or initiate movement. of gai
One of the most recent and remarkable scientific developments has been the ability of scientists to manipulate somatic cells (e.g.
An important article appeared in the December 2010 Lancet Neurology issue (early view) featuring research from one of the Parkinson's Foundation Centers of Excellence in the Netherlands (Center Director- Bas Bloem). Munneke and colleagues from that center introduced the ParkinsonNet concept; a framework aimed at igniting a sea change in PD-related care.
There have been more than a few theories over the span of many years regarding the pathogenesis of Parkinson’s disease (PD). Recent findings have implicated problems with mitochondrial dysfunction, oxidative stress, and protein misfolding/aggregation along with genetic/environmental issues. Additionally, PD is now appreciated to be more than a single disorder, and is now considered a syndrome that may have multiple underlying causes usually occurring with similar clinical manifestations.